JP2023518038A5 - - Google Patents

Info

Publication number
JP2023518038A5
JP2023518038A5 JP2022555643A JP2022555643A JP2023518038A5 JP 2023518038 A5 JP2023518038 A5 JP 2023518038A5 JP 2022555643 A JP2022555643 A JP 2022555643A JP 2022555643 A JP2022555643 A JP 2022555643A JP 2023518038 A5 JP2023518038 A5 JP 2023518038A5
Authority
JP
Japan
Prior art keywords
amino acid
modified polypeptide
coronavirus
cov
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022555643A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518038A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/022611 external-priority patent/WO2021188576A1/en
Publication of JP2023518038A publication Critical patent/JP2023518038A/ja
Publication of JP2023518038A5 publication Critical patent/JP2023518038A5/ja
Pending legal-status Critical Current

Links

JP2022555643A 2020-03-16 2021-03-16 改変されたアンジオテンシン変換酵素２（ａｃｅ２）またはその使用 Pending JP2023518038A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202062989976P 2020-03-16 2020-03-16
US62/989,976 2020-03-16
US202063022151P 2020-05-08 2020-05-08
US63/022,151 2020-05-08
US202063042907P 2020-06-23 2020-06-23
US63/042,907 2020-06-23
US202063089895P 2020-10-09 2020-10-09
US63/089,895 2020-10-09
PCT/US2021/022611 WO2021188576A1 (en) 2020-03-16 2021-03-16 Modified angiotensin-converting enzyme 2 (ace2) and use thereof

Publications (2)

Publication Number Publication Date
JP2023518038A JP2023518038A (ja) 2023-04-27
JP2023518038A5 true JP2023518038A5 (https=) 2024-02-29

Family

ID=75439530

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022555643A Pending JP2023518038A (ja) 2020-03-16 2021-03-16 改変されたアンジオテンシン変換酵素２（ａｃｅ２）またはその使用

Country Status (8)

Country Link
US (1) US20230193235A1 (https=)
EP (1) EP4121170A1 (https=)
JP (1) JP2023518038A (https=)
KR (1) KR20220154796A (https=)
AU (1) AU2021239879A1 (https=)
BR (1) BR112022018527A2 (https=)
CA (1) CA3174683A1 (https=)
WO (1) WO2021188576A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116057176A (zh) * 2020-03-21 2023-05-02 赖瑞克斯生物科技公司 Ace2和补体途径的双特异性和三特异性功能分子及其用途
EP3884957A1 (en) * 2020-03-26 2021-09-29 The University of British Columbia Methods for treatment of virus and methods for screening of anti-virus reagent using organoids
US20230257726A1 (en) * 2020-05-11 2023-08-17 Chan Zuckerberg Biohub, Inc. Ace2 compositions and methods
IL276627A (en) * 2020-08-10 2022-03-01 Yeda Res & Dev Compositions for diagnosis and treatment of coronavirus infections
CN117120621A (zh) * 2020-11-12 2023-11-24 上海科技大学 提高效率和准确性的基因组编辑
JP2024540722A (ja) * 2021-11-01 2024-11-01 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 変異型アンジオテンシン変換酵素２（ａｃｅ２）を含む組換え／融合ポリペプチド
WO2023081958A1 (en) * 2021-11-11 2023-05-19 The Macfarlane Burnet Institute For Medical Research And Public Health Ltd Antiviral agent comprising a cellular entry receptor and fc region component
CN114606219B (zh) * 2022-04-01 2023-10-31 北京大学 一种冠状病毒中和效应蛋白及其应用
EP4507787A1 (en) * 2022-04-13 2025-02-19 Paradigm Immunotherapeutics, Inc. Methods of preventing or treating infection by respiratory viruses including sars-cov-2
CN117304317B (zh) * 2022-06-28 2024-08-02 四川大学 Ace2受体特异性结合肽及其应用
EP4386084A1 (en) * 2022-12-14 2024-06-19 Formycon AG Improved ace2 fusion proteins
WO2024215776A1 (en) * 2023-04-10 2024-10-17 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Recombinant ace2 polypeptide and uses thereof
KR20240177843A (ko) * 2023-06-20 2024-12-30 주식회사 엔큐라젠 SARS-CoV-2스파이크 단백질에 특이적으로 결합하는 펩타이드 및 이의 용도
CN117447609A (zh) * 2023-10-25 2024-01-26 山西锦波生物医药股份有限公司 灭活冠状病毒的融合蛋白及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1515752E (pt) * 2002-06-19 2009-03-05 Univ Health Network Activação de ace2 para o tratamento de doença cardíaca, pulmonar e renal e de hipertensão
AU2013216910A1 (en) * 2012-02-10 2014-08-28 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of peripheral vascular disease

Similar Documents

Publication Publication Date Title
JP2023518038A5 (https=)
CN115244077B (zh) 蛋白质治疗剂
JP2023518038A (ja) 改変されたアンジオテンシン変換酵素２（ａｃｅ２）またはその使用
IL321500A (en) Pre-stabilized hmpv f proteins
JP7554837B2 (ja) 可溶性ａｃｅ２及び融合タンパク質、並びにその適用
US20230174611A1 (en) Compositions and methods for preventing or reducing the effects of infections by coronaviruses that bind the extracellular domain of the ace2 receptor
CN105934249A (zh) 用于治疗肺高压的组合物和方法
EP4217370A2 (en) Methods and compositions for treating coronaviral infections
WO2021247675A1 (en) Coronavirus-binding agents and uses thereof
JP2025170319A (ja) Ｓａｒｓ－ｃｏｖ－２阻害剤
JP2007526213A (ja) コロナウイルスによる感染症の治療、管理および予防用の抗ウイルス剤
CN114364394A (zh) 用于治疗冠状病毒感染及相关凝血病的方法和组合物
US20170198014A1 (en) Polypeptides and their use for treating influenza
WO2024229151A2 (en) Multimeric coronavirus binding molecules and uses thereof
CN113993884A (zh) 抑制呼吸道合胞病毒感染的生物及合成分子
JP2024516605A (ja) コロナウイルス感染を処置するための新規組成物及び方法
RU2837537C1 (ru) Растворимый апф2, его слитый белок и способы их применения
US20240025972A1 (en) Methods for modulating host cell surface interactions with sars-cov-2
TWI920168B (zh) 調節宿主細胞表面與ｓａｒｓ-ｃｏｖ-２交互作用之方法
US20240293505A1 (en) Reversal of ctl exhaustion with annexin v
WO2022034588A1 (en) Compositions for diagnosis and treatment of coronavirus infections
ZA200509512B (en) Antiviral agents for the treatment, control and prevention of infections by coronaviruses
HK40107422A (zh) 用於调节宿主细胞表面与sars-cov-2相互作用的方法
WO2022146154A2 (en) Peptide for use in the treatment or prevention of covid-19
CN117659181A (zh) 针对sars-cov-2刺突蛋白的肽治疗剂